SWOG clinical trial number
S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Closed
Phase
Accrual
100%
Abbreviated Title
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL
Status Notes
Temporary Closure: Effective Wednesday, October 05, 2022, 12:00 p.m. Pacific Time
Activated
07/19/2019
Closed
12/01/2022
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lymphoma
Treatment
Doxorubicin
Filgrastim
Vinblastine Sulfate
Radiation Therapy
Pegfilgrastim
Nivolumab
Brentuximab Vedotin
Dacarbazine
RT
Eligibility Criteria Expand/Collapse
See Section 5.0 of the S1826 protocol posted on www.ctsu.org
Publication Information Expand/Collapse
2021
An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826
Addressing the Paucity of AYA Clinical Trials Through Pediatric and Adult Partnership
2020
PMid: PMID32917781
Other Clinical Trials
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Research Committee(s)
Lymphoma
Activated
06/07/2021
Open
Phase
SWOG Clinical Trial Number
S1918
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Research Committee(s)
Lymphoma
Activated
03/19/2021
Accrual
14%
Open
Phase